piroxicam

1. The gastrointestinal adverse reaction of piroxicam which is non-selective non-steroidal anti-inflammatory drug has been of great concern.
   非选择性非甾体抗炎药吡罗昔康的胃肠道不良反应一直受到关注。
2. Therefore, it provide experimental basis on the clinical use of Piroxicam to prevent gastric cancer.
   这些结果从细胞免疫方面为吡罗昔康能够防治胃癌提供了一定的实验依据。
3. Determination of Piroxicam in human plasma by HPLC
   HPLC测定人血浆中吡罗昔康的浓度
4. The Agency's Committee for Medicinal Products for Human Use ( CHMP) has concluded that piroxicam's benefits still outweigh its risks, but, based on safety grounds, only in certain, limited indications.
   该局人用药品委员会（CHMP）的结论认为，吡罗昔康的益处仍大于其风险，但是，基于安全方面的考虑，其应用仅限于某些特定的适应症。
5. Piroxicam is known as a non-selective NSAID because it acts on all types of the cyclo-oxygenase enzyme, including one type that is involved in the inflammatory process.
   吡罗昔康是一种非选择性非类固醇抗炎药，作用于包括参与炎症过程的一类环氧酶在内的所有类型的环氧酶。
6. In vitro evaluation and local tissue distribution of piroxicam Pluronic lecithin organogel
   吡罗昔康普朗尼克磷脂有机凝胶的体外评价和局部组织分布
7. The European Medicines Agency ( EMEA) has recently completed a review of the safety of the non-steroidal anti-inflammatory drug ( NSAID) piroxicam.
   欧洲药品管理局（EMEA）最近完成了有关非类固醇抗炎药（NSAID）吡罗昔康的安全性评价。
8. In addition, the CHMP added some contraindications and strengthened warnings for piroxicam, to ensure that it is not used in patients who are at a higher risk of developing side effects.
   此外，CHMP还增加了吡罗昔康某些禁忌症并强调了警告信息，以确保不用于那些出现副作用的高危患者。
9. Consequently, the European Commission asked the CHMP to carry out a full assessment of the benefit-risk balance of piroxicam.
   鉴于此，欧盟要求CHMP对吡罗昔康的受益与风险进行全面评价。
10. OBJECTIVE To investigate the transdermal iontophoresis of piroxicam gel in vitro.
    目的考察吡罗昔康凝胶的体外经皮离子导入。
11. Preparation and percutaneous absorption of piroxicam ointment bases
    炎痛喜康软膏的制备及兔透皮吸收
12. Double-peak phenomenon of piroxicam pharmacokinetics
    炎痛喜康药物动力学的双峰现象
13. The proposed method was simple, accurate, specific and applicable to the analysis of Piroxicam gel and quality control.
    方法简单，准确度高，专属性强，可用于吡罗昔康凝胶样品的稳定性考察和质量控制。
14. Conclusion The pharmacokinetics of piroxicam patch in the dosage of 48~ 144 mg in human body nearly fit linear dynamic feature and have the feature of transdermal drug delivery system comparing with piroxicam capsule and freeze-dried tablet.
    结论在48~144mg内，吡罗昔康贴片具有线性动力学特征，和口服吡罗昔康相比，吡罗昔康贴片具备经皮给药系统的特征。
15. A test on the transdermal absorption of piroxicam Lotion
    吡罗昔康搽剂的透皮吸收试验
16. The plasma drug levels of eight healthy volunteers following oral administration ( 20mg) of conventional and controlled-release piroxicam tablets in a crossover design were determined.
    本文应用高效液相色谱法测定了8名健康受试者自身交叉服用炎痛喜康普通片与控释片（分别服用单剂量20mg）后的血药浓度。
17. Presented in this article is a test on the transdermal absorption of piroxicam lotion by in vitro method. The result shows that the relationship between the concentration of the lotion and the amount of transdermal absorption is interdependent.
    本文介绍了利用体外法研究吡罗昔康搽剂的透皮吸收试验，结果表明搽剂浓度与透皮渗透药量之间有依存关系。
18. In vitro and in vivo characteristics of two dosage forms of piroxicam solid dispersion system with different PEG bases
    吡罗昔康PEG固体分散体中载体组成与制剂的体内外特性
19. Study on transdermal iontophoresis of piroxicam gel
    吡罗昔康凝胶离子导入经皮给药研究
20. Piroxicam patch in treatment of acute and chronic pain: a multicenter, randomized and controlled clinical study
    吡罗昔康透皮控释贴片治疗急慢性疼痛多中心随机对照临床研究
21. Use of first-order derivative UV spectroscopy in monitoring the percutaneous absorption of piroxicam in vitro
    一阶导数紫外光谱法测定炎痛喜康透皮速率
22. Preliminary investigation for piroxicam tablets
    不同炎痛喜康片的初步研究
23. Comparison of concentration of piroxicam in blood and local site
    吡罗昔康两种给药途径的血药浓度与局部浓度比较
24. In order to decrease the irritation of Piroxicam tablets to gastrointestinal tract the preparation of Piroxicam ointment bases and their percutaneous absorption were studied.
    为避开炎痛喜康片剂对胃肠道的刺激性，本文研究了炎痛喜康软膏剂的制备及其透皮吸收过程。
25. RESULTS: A total of 210 patients with acute or chronic pain were enrolled in the study, including 106 patients completed the study in the trial ( piroxicam) group and 104 patients in the control ( diclofenac) group.
    结果：210例病人入选，试验组（吡罗昔康组）106例，对照组（双氯芬酸组）104例。
26. The usage of piroxicam and patient dependence: A clinical study
    吡罗昔康用法与病人依从性研究
27. CONCLUSION: Piroxicam patch shows better efficacy and similar safety in the treatment of acute and chronic pain in comparing with diclofenac.
    结论：吡罗昔康贴片治疗急慢性疼痛多项疗效指标结果优于双氯芬酸乳胶，安全性与双氯芬酸乳胶相似。
28. The Piroxicam in the ointment bases was stable and had only very slight irritation to rabbit skin.
    研制的炎痛喜康软膏剂物理性能较稳定，对家兔皮肤的刺激性很小。
29. Objective To observe the acute cytotoxic effect and apoptosis of sonodynamic therapy ( SDT) with piroxicam on human mammary cancer cell line MDA-MB-231 and explore its potential mechanism.
    目的探讨吡罗昔康介导的声动力效应对乳腺癌细胞的急性细胞毒作用及其作用机制。
30. Objective To study the inclusion interaction of piroxicam ( PX) with cyclodextrin derivatives ( CDs).
    目的旨在研究环糊精衍生物（CDs）与吡罗昔康（PX）的包合作用。

noun

1. a nonsteroidal anti-inflammatory drug (trade name Feldene) used to treat arthritis and other inflammatory conditions

   Synonym:    Feldene